RPT-GCN2i for Oncology
GCN2 is a fundamental driver of immune suppression and the survival of tumor cells under conditions of metabolic stress typically seen in the tumor microenvironment. Preclinical studies have shown that the inhibition of GCN2 results in tumor cell death in vitro and restoration of immune function under these stress conditions. The GCN2 pathway is generally not active in healthy tissue suggesting the potential for a favorable therapeutic index for drugs targeting GCN2. Our lead molecule has demonstrated the ability to restore T cell proliferation and function in nutrient-deprived conditions, to overcome immune suppression induced by myeloid-derived suppressor cells (MDSC), and to elicit antitumor responses in animal models. We anticipate filing an investigational new drug application (IND) with the U.S. Food and Drug Administration on a GCN2 inhibitor in 2020.